SHILPA PHARMA LIFESCIENCES 24/7 BIOPHARMA had the opportunity to sit down with representatives of Shilpa Pharma Lifesciences, a wholly owned subsidiary of Shilpa Medicare, to discuss the company’s role in the CDMO space. These individuals were Keshav Bhutada, Executive Director, and Dr. Harshawardhan Bal, company President. In this interview, Bhutada and Bal spoke on the hybrid structure of the CDMO and how the company is continually expanding to tackle key market trends. Embracing the hybrid model A natural part of the jockeying process in the highly competitive CDMO space is finding a unique pitch. For Shilpa Pharma, this pitch focuses on what the company representatives call a hybrid CDMO model, which they define as a broad range of complementary services that can meet clients where they’re at in the pharmaceutical development process. “The hybrid model represents flexibility and openness to have different partnership models and not being tied to the traditional CDMO model,” said Bhutada. “The hybrid model supports both generic pharma business companies as well as biotech companies... We have several generic products where we offer both API and formulations to some differentiated products that are more value-added to generic companies. And then we have a service offering where there is a separate team which only gives support to complete NCE and NBE programs with a very strong track record of regulatory approvals as well as accreditations.” In short, the goal of this model is tailoring operations to any client’s needs in an agile and receptive way. One aspect of this is the structure of the business agreement, which can deviate from typical CDMO payment schemes (such as the full-time-equivalent, or FTE, model) to more fluid, negotiable structures. In this vein, they adjust to the situation of their TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 50
RkJQdWJsaXNoZXIy MjY2OTA4MA==